121 related articles for article (PubMed ID: 8754652)
41. Chemotherapy accelerates the development of acquired immune responses to Schistosoma haematobium infection.
Mutapi F; Ndhlovu PD; Hagan P; Spicer JT; Mduluza T; Turner CM; Chandiwana SK; Woolhouse ME
J Infect Dis; 1998 Jul; 178(1):289-93. PubMed ID: 9652458
[TBL] [Abstract][Full Text] [Related]
42. Treatment of human acute schistosomiasis with oxamniquine induces an increase in interferon-gamma response to Schistosoma mansoni antigens.
de Souza JR; Morais CN; Aroucha ML; Miranda PJ; Barbosa CS; Domingues AL; Carvalho Júnior LB; Abath FG; Montenegro SM
Mem Inst Oswaldo Cruz; 2007 May; 102(2):225-8. PubMed ID: 17426890
[TBL] [Abstract][Full Text] [Related]
43. Clinical, parasitological and immunological features of canal cleaners hyper-exposed to Schistosoma mansoni in the Sudan.
Satti MZ; Sulaiman SM; Homeida MM; Younis SA; Ghalib HW
Clin Exp Immunol; 1996 Jun; 104(3):426-31. PubMed ID: 9099926
[TBL] [Abstract][Full Text] [Related]
44. Effect of praziquantel on certain immune responses of schistosomal Egyptian patients. I. Changes of specific immunoglobulins.
Shaker ZA; Hassanein HI; Kamel MM; el-Bahairy NM; el-Kalouby AH; el-Raziky EH
Parasitol Res; 1987; 73(4):328-33. PubMed ID: 3112768
[TBL] [Abstract][Full Text] [Related]
45. Anti-schistosome IgG4 and IgE at 2 years after chemotherapy: infected versus uninfected individuals.
Grogan JL; Kremsner PG; van Dam GJ; Deelder AM; Yazdanbakhsh M
J Infect Dis; 1997 Nov; 176(5):1344-50. PubMed ID: 9359737
[TBL] [Abstract][Full Text] [Related]
46. Decay of antibody isotypes against early developmental stages of Schistosoma mansoni after treatment of schistosomiasis patients.
Kanamura HY; Hoshino-Shimizu S; Kimura RT; Matsumoto TK; da Silva LC; Lima DM; Abrantes-Lemos CP
Rev Inst Med Trop Sao Paulo; 1997; 39(5):271-7. PubMed ID: 9661305
[TBL] [Abstract][Full Text] [Related]
47. Long-term evaluation of patients with hydatidosis treated with albendazole and praziquantel.
Haralabidis S; Diakou A; Frydas S; Papadopoulos E; Mylonas A; Patsias A; Roilides E; Giannoulis E
Int J Immunopathol Pharmacol; 2008; 21(2):429-35. PubMed ID: 18547489
[TBL] [Abstract][Full Text] [Related]
48. Serum antibody responses in opisthorchiasis.
Akai PS; Pungpak S; Chaicumpa W; Kitikoon V; Ruangkunaporn Y; Bunnag D; Befus AD
Int J Parasitol; 1995 Aug; 25(8):971-3. PubMed ID: 8550296
[TBL] [Abstract][Full Text] [Related]
49. Efficacy of an enzyme-linked immunosorbent assay in the diagnosis of and serologic distinction between acute and chronic Schistosoma mansoni infection.
Valli LC; Kanamura HY; Da Silva RM; Silva MI; Vellosa SA; Garcia ET
Am J Trop Med Hyg; 1997 Sep; 57(3):358-62. PubMed ID: 9311650
[TBL] [Abstract][Full Text] [Related]
50. Effects of calcitriol on eosinophil activity and antibody responses in patients with schistosomiasis.
Snyman JR; de Sommers K; Steinmann MA; Lizamore DJ
Eur J Clin Pharmacol; 1997; 52(4):277-80. PubMed ID: 9248764
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of Echinostoma liei worm, metacercaria and redia antigens for schistosomiasis control.
Abdel-Monaem G; Farid A; Rabia I; El-Amir A
Exp Parasitol; 2015 Oct; 157():23-9. PubMed ID: 26115938
[TBL] [Abstract][Full Text] [Related]
52. IgG subclasses in human chronic schistosomiasis: over-production of schistosome-specific and non-specific IgG4.
Boctor FN; Peter JB
Clin Exp Immunol; 1990 Dec; 82(3):574-8. PubMed ID: 2265494
[TBL] [Abstract][Full Text] [Related]
53. Studies on schistosomiasis in western Kenya: II. Efficacy of praziquantel for treatment of schistosomiasis in persons coinfected with human immunodeficiency virus-1.
Karanja DM; Boyer AE; Strand M; Colley DG; Nahlen BL; Ouma JH; Secor WE
Am J Trop Med Hyg; 1998 Aug; 59(2):307-11. PubMed ID: 9715952
[TBL] [Abstract][Full Text] [Related]
54. Resistance to Schistosoma mansoni in humans: influence of the IgE/IgG4 balance and IgG2 in immunity to reinfection after chemotherapy.
Demeure CE; Rihet P; Abel L; Ouattara M; Bourgois A; Dessein AJ
J Infect Dis; 1993 Oct; 168(4):1000-8. PubMed ID: 7690821
[TBL] [Abstract][Full Text] [Related]
55. Enzyme-linked immunosorbent assay (ELISA) for detecting IgM and IgE antibodies in human schistosomiasis.
Lunde MN; Ottesen EA
Am J Trop Med Hyg; 1980 Jan; 29(1):82-5. PubMed ID: 6986098
[TBL] [Abstract][Full Text] [Related]
56. Changes in specific anti-egg antibody levels following treatment with praziquantel for Schistosoma haematobium infection in children.
Mutapi F; Ndhlovu PD; Hagan P; Woolhouse ME
Parasite Immunol; 1998 Dec; 20(12):595-600. PubMed ID: 9990644
[TBL] [Abstract][Full Text] [Related]
57. Humoral immune responses in patients with acute Schistosoma mansoni infection who were followed up for two years after treatment.
Rabello AL; Garcia MM; Pinto da Silva RA; Rocha RS; Katz N
Clin Infect Dis; 1997 Mar; 24(3):304-8. PubMed ID: 9114177
[TBL] [Abstract][Full Text] [Related]
58. Antibody response in mice infected with Mesocestoides vogae (syn. Mesocestoides corti) tetrathyridia after treatment with praziquantel and liposomised glucan.
Hrckova G; Velebný S; Kogan G
Parasitol Res; 2007 May; 100(6):1351-9. PubMed ID: 17252273
[TBL] [Abstract][Full Text] [Related]
59. The efficacy of human schistosomicide treatment may depend on the rate of transmission.
García N; Isturiz G; Aular S; Incani RN
Parasitol Res; 2006 May; 98(6):545-9. PubMed ID: 16418873
[TBL] [Abstract][Full Text] [Related]
60. Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.
Butterworth AE; Capron M; Cordingley JS; Dalton PR; Dunne DW; Kariuki HC; Kimani G; Koech D; Mugambi M; Ouma JH
Trans R Soc Trop Med Hyg; 1985; 79(3):393-408. PubMed ID: 4035741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
